Non-alcoholic Fatty Liver Disease: all 1,507 studies

Page 5 of 16. Open to participants first (303), then studies with results posted, then the rest; newest registration first within each.

• Study of Gemcabene in Adults With FPLDCompletedNCT03508687Phase 1/2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedNCT03486912Phase 2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedNCT03486899Phase 2Results posted
• Losartan for the Treatment of Pediatric NAFLDTerminatedNCT03467217Phase 2Results posted
• Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseCompletedNCT03459079Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedNCT03449446Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompletedNCT03439254Phase 3Results posted
• Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14CompletedNCT03439189Results posted
• Gemcabene for the Treatment of Pediatric NAFLDTerminatedNCT03436420Phase 2Results posted
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic SteatohepatitisCompletedNCT03421431Phase 2Results posted
• A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT03400163Phase 2Results posted
• Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskCompletedNCT03375788Phase 2Results posted
• Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseCompletedNCT03371355Phase 2Results posted
• Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot StudyCompletedNCT03339245Not applicableResults posted
• A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious PsoriasisTerminatedNCT03329885Phase 1/2Results posted
• The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and PhysiologyTerminatedNCT03294941Phase 2Results posted
• Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric SurgeryCompletedNCT03294850Not applicableResults posted
• 6-week Safety and PD Study in Adults With NAFLDCompletedNCT03256526Phase 2Results posted
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03248882Phase 2Results posted
• Effect of LIK066 on Reduction of Fatty Content in Livers of Obese PatientsCompletedNCT03205150Phase 2Results posted
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASHCompletedNCT03166735Phase 2Results posted
• Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in JapanCompletedNCT03143166Phase 1Results posted
• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisCompletedNCT03061721Phase 2Results posted
• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic SteatohepatitisTerminatedNCT03059446Phase 2Results posted
• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03053063Phase 3Results posted
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisTerminatedNCT03053050Phase 3Results posted
• Anti-LPS Antibody Treatment for Pediatric NAFLDCompletedNCT03042767Phase 2Results posted
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03028740Phase 3Results posted
• Palliative Care for Non-Malignant Diseases (COMPASS Trial)TerminatedNCT03022630Not applicableResults posted
• Phase 2b Study in NASH to Assess IVA337CompletedNCT03008070Phase 2Results posted
• A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in CanadaCompletedNCT02985450Results posted
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.CompletedNCT02970942Phase 2Results posted
• Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal HypertensionCompletedNCT02960204Phase 2Results posted
• Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLDCompletedNCT02941549Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASHTerminatedNCT02913105Phase 2Results posted
• Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT02912260Phase 2Results posted
• Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic FunctionCompletedNCT02891408Phase 1Results posted
• EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and ObesityCompletedNCT02880189Not applicableResults posted
• Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)CompletedNCT02875392Not applicableResults posted
• Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic SteatohepatitisCompletedNCT02856555Phase 2Results posted
• Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)TerminatedNCT02855164Phase 2Results posted
• Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT02854605Phase 2Results posted
• Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic FunctionCompletedNCT02808312Phase 1Results posted
• Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT02787304Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASHCompletedNCT02784444Phase 2Results posted
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)CompletedNCT02781584Phase 2Results posted
• Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in AdolescentsCompletedNCT02726542Early Phase 1Results posted
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT02704403Phase 3Results posted
• Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and LipodystrophyCompletedNCT02684591Phase 2Results posted
• Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD SubjectsCompletedNCT02681055Phase 2Results posted
• CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial LipodystrophyCompletedNCT02654977Phase 2Results posted
• Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and PharmacodynamicsCompletedNCT02654002Phase 1Results posted
• A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)CompletedNCT02653300Phase 2Results posted
• Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)CompletedNCT02633956Phase 2Results posted
• Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT02605616Phase 2Results posted
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentTerminatedNCT02548351Phase 3Results posted
• The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver DiseaseCompletedNCT02546609Phase 2Results posted
• The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/SteatohepatitisCompletedNCT02528305Not applicableResults posted
• Dietary Treatment Study of Pediatric NAFLDCompletedNCT02513121Not applicableResults posted
• Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)TerminatedNCT02500147Phase 4Results posted
• Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3CompletedNCT02466516Phase 2Results posted
• Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT02443116Phase 2Results posted
• JKB-121 for the Treatment of Nonalcoholic SteatohepatitisCompletedNCT02442687Phase 2Results posted
• Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced FibrosisCompletedNCT02421094Phase 2Results posted
• A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT02413372Phase 2Results posted
• Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT02369536Not applicableResults posted
• Fatty Liver Study in Patients With Type II DiabetesTerminatedNCT02365233Phase 4Results posted
• A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.CompletedNCT02354976Phase 2Results posted
• ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLDCompletedNCT02330549Phase 2Results posted
• A Phase ll Study of IMM-124E for Patients With Non-alcoholic SteatohepatitisCompletedNCT02316717Phase 2Results posted
• BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASHCompletedNCT02314026Phase 2Results posted
• Effects of Pitavastatin on Insulin Sensitivity and Liver FatCompletedNCT02290106Not applicableResults posted
• Safety and Tolerability Study of SHP626 in Overweight and Obese AdultsCompletedNCT02287779Phase 1Results posted
• A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASHCompletedNCT02279524Phase 2Results posted
• Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLDTerminatedNCT02244944Phase 2Results posted
• Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver FibrosisCompletedNCT02217475Phase 2Results posted
• Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver DiseaseCompletedNCT02217345Phase 2Results posted
• Tesamorelin Effects on Liver Fat and Histology in HIVCompletedNCT02196831Not applicableResults posted
• The Role of Obstructive Sleep Apnea in Children With Fatty Liver DiseaseTerminatedNCT02134522Not applicableResults posted
• Ultrasound Method to Measure Fibrosis of the Liver in ChildrenTerminatedNCT02086708Not applicableResults posted
• A Study of IDN-6556 in Subjects With NAFLD and Raised TransaminasesCompletedNCT02077374Phase 2Results posted
• Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic PatientsCompletedNCT01975935Phase 2Results posted
• Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver DiseaseCompletedNCT01963845Phase 2Results posted
• Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver DiseaseTerminatedNCT01930123Phase 2Results posted
• Study of Losartan in the Treatment of NAFLD in ChildrenCompletedNCT01913470Phase 2Results posted
• Effect of Phytosterols on Nonalcoholic Fatty Liver DiseaseCompletedNCT01875978Not applicableResults posted
• Amlexanox for Type 2 Diabetes and ObesityTerminatedNCT01842282Phase 2Results posted
• Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD PatientsCompletedNCT01811472Phase 2Results posted
• Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin ECompletedNCT01792115Phase 2Results posted
• How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?CompletedNCT01790984Not applicableResults posted
• Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic SyndromeCompletedNCT01787591Not applicableResults posted
• Ezetimibe Versus Placebo in the Treatment of Non-alcoholic SteatohepatitisCompletedNCT01766713Phase 2Results posted
• Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control GroupCompletedNCT01754714Phase 3Results posted
• Sonoelastography: Ultrasound Method to Measure Liver FibrosisCompletedNCT01747772Not applicableResults posted
• Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver DiseaseCompletedNCT01712711Phase 2Results posted
• Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitisTerminatedNCT01703260Phase 2Results posted
• Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT01694849Phase 2Results posted
• Investigation of Synbiotic Treatment in NAFLDCompletedNCT01680640Not applicableResults posted
• Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With LipodystrophyCompletedNCT01679197Phase 2Results posted
• Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)TerminatedNCT01672866Phase 2Results posted

← Non-alcoholic Fatty Liver Disease overview